Omeros Corporation (OMER) 11.45 $OMER
Omeros Corporation Confirms OMS721 Phase 3 Development Plan with European Medicines Agency
PR Newswire - Thu Jul 28, 8:27AM CDT
Omeros Corporation (NASDAQ: OMER) today announced that it has received scientific advice from the European Medicines Agency (EMA) in connection with the company's OMS721 Phase 3 program for the treatment of atypical hemolytic uremic syndrome (aHUS). Based on this EMA advice, the company plans to run the same, single Phase 3 clinical program to support OMS721 marketing approval applications in both the U.S. and in the European Union for the treatment of aHUS. OMS721 is Omeros' lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of thrombotic microangiopathies (TMAs), including aHUS and hematopoietic stem cell transplant-related (HSCT) TMAs, and for the treatment of complement-related renal diseases. Omeros plans to commercialize OMS721 initially for administration as a subcutaneous injection.
OMER: 11.45 (-0.35)
Omeros to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
BusinessWire - Thu Jul 07, 6:00AM CDT
Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference in New York next week. The presentation is scheduled for Tuesday, July 12, 2016 at 10:45 a.m. EDT.
OMER: 11.45 (-0.35)
The Sub $1 Stock in the $800 Billion Cigarette Industry the Tobacco Giants Need to Stay Relevant
ACCESSWIRE - Mon May 23, 6:00AM CDT
WINDSOR, ON / ACCESSWIRE / May 23, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to bring to investors' attention how one little-known company, 22nd Century Group (NYSE MKT: XXII), has developed a revolutionary combustible cigarette that could give smokers exactly what they have been seeking, and drastically change the tobacco industry in the process.
RAI: 49.84 (unch), PM: 99.89 (-0.26), BTI: 128.20 (+1.62), XXII: 0.91 (-0.01), MO: 67.57 (-0.08), ARDM: 4.78 (+0.11), OMER: 11.45 (-0.35)
Omeros Announces Debt Financing Transaction for $20 Million in Additional Funds
BusinessWire - Tue May 17, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) (the "Company" today announced that it has entered into an amendment to its existing credit facility with Oxford Finance LLC ("Oxford" and East West Bank ("East West" to provide the Company with an additional $20 million in unrestricted cash by funding the remaining tranches of the facility. Omeros will issue warrants to the lenders, exercisable for seven years for up to 100,602 shares of the Company's common stock at an exercise price per share of $9.94, the closing price of the Company's stock on May 16, 2016. All loan payments will be interest-only until August 1, 2017. The final payment fee rate on the $20 million borrowed will increase from 5.25% to 6.25%, reflecting the accelerated draw-down of these additional funds. Omeros expects funding will occur on May 18, 2016.
OMER: 11.45 (-0.35)
Omeros reports 1Q loss
Automated Insights - Tue May 10, 6:26AM CDT
SEATTLE (AP) _ Omeros Corporation (OMER) on Tuesday reported a loss of $20.5 million in its first quarter.
OMER: 11.45 (-0.35)
Omeros Corporation Reports First Quarter 2016 Financial Results
BusinessWire - Tue May 10, 6:20AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the first quarter of 2016, which include:
OMER: 11.45 (-0.35)
Omeros Corporation Announces Exclusive Middle East Distribution Agreement for OMIDRIA(R)
BusinessWire - Tue May 10, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced entry into an exclusive supply and distribution agreement for the sale of OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% in the Kingdom of Saudi Arabia, the United Arab Emirates and other countries in the Middle East with ITROM Trading Drug Store (ITROM). ITROM is Dubai-based and an internationally recognized pharmaceutical marketing and distribution company specializing in ophthalmology. Under the agreement, ITROM will be responsible for obtaining marketing authorizations for OMIDRIA within the licensed territory and for marketing, selling and distributing product supplied by Omeros. Existing ophthalmology medical sales representatives employed by ITROM are expected to be reinforced with additional medical sales representatives that will be dedicated to OMIDRIA.
OMER: 11.45 (-0.35)
Omeros Corporation to Announce First Quarter 2016 Financial Results on May 10, 2016
BusinessWire - Wed May 04, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its first quarter 2016 financial results for the period ended March 31, 2016, on Tuesday, May 10, 2016, before the market opens. Omeros management will host a conference call and webcast that day at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) to discuss the financial results.
OMER: 11.45 (-0.35)
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 4.23 (+0.04), CBMG: 14.72 (-0.10), OCAT: 8.47 (+0.01), ZBH: 129.94 (-1.12), PFE: 36.37 (-0.94), LLY: 82.90 (-0.28), GSK: 45.28 (+0.03), GLPG: 52.66 (-0.48), AXSM: 7.67 (-0.12), OMER: 11.45 (-0.35), CANF: 2.07 (-0.03), AST: 2.94 (unch), AKTX: 11.50 (unch)
Omeros Corporation Announces Independent Studies with OMIDRIA(R) to Be Presented at Upcoming Ophthalmology Congresses
BusinessWire - Tue Apr 26, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that new research related to the clinical utility of OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% and the importance of preempting intraoperative miosis and inflammation during cataract surgery will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting in Seattle, Washington, May 1 - 5, 2016, and the American Society of Cataract and Refractive Surgery (ASCRS) Congress in New Orleans, Louisiana, May 6 - 10, 2016. Presentations will address the beneficial effects demonstrated in case-controlled studies of OMIDRIA on complication rates, on use of pupil-expanding devices, on surgical times and on postoperative visual acuity.
OMER: 11.45 (-0.35)
Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases
BusinessWire - Wed Apr 20, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced initiation of patient dosing in its OMS721 Phase 2 program in corticosteroid-dependent renal diseases. The Phase 2 clinical trial of OMS721, the company's lead mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor being developed for complement-related diseases, is evaluating the effects of OMS721 on kidney function in patients with corticosteroid-dependent renal diseases. This new trial expands the company's MASP platform, which includes an OMS721 Phase 3 program in progress for the treatment of atypical hemolytic uremic syndrome (aHUS) as well as an ongoing Phase 2 program of OMS721 for the treatment of other thrombotic microangiopathies (TMAs).
OMER: 11.45 (-0.35)
Restless Legs Syndrome Pipeline Market 2016 Review Research
PR Newswire - Mon Apr 11, 7:30AM CDT
New market research titled "Restless Legs Syndrome - Pipeline Review, H1 2016" is a report that provides an overview of the Restless Legs Syndrome's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
OMER: 11.45 (-0.35)
Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 1.95 (-0.02), OMER: 11.45 (-0.35), ATHX: 2.16 (-0.01), KPTI: 7.06 (-0.17), CUR: 0.22 (-0.01)
Omeros to Present at the 15th Annual Needham Healthcare Conference
BusinessWire - Thu Apr 07, 6:00AM CDT
Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 15th Annual Needham Healthcare Conference in New York next week. The presentation is scheduled for Wednesday, April 13, 2016, at 2:20 p.m. EDT.
OMER: 11.45 (-0.35)
Is This Upstart the Biggest Threat to Alexion Pharmaceuticals?
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 11, 8:02AM CST
Image source: Alexion Pharmaceuticals. Alexion Pharmaceuticals is a big player in the treatment of rare diseases, but its dominance in atypical hemolytic uremic syndrome (aHUS) could be in jeopardy if a soon-to-begin clinical trial at Omeros...
ALXN: 131.32 (-2.18), OMER: 11.45 (-0.35)
Atherosclerosis Pipeline: H2 2015 World Market Research Report
PR Newswire - Wed Mar 09, 6:30AM CST
Market research report titled "Atherosclerosis - Pipeline Review, H2 2015" provides an overview of the Atherosclerosis's therapeutic pipeline and enhances decision making capabilities to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
JNJ: 124.65 (-0.75), VCEL: 2.27 (+0.05), KNMD: (), OPK: 9.91 (-0.16), GILD: 80.19 (-0.27), MRK: 58.45 (-0.21), AZN: 33.86 (+0.02), OMER: 11.45 (-0.35)
Why Calavo Growers, Thor Industries, and Omeros Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Tue Mar 08, 6:45PM CST
Image: Calavo Growers. Tuesday ended the stock market's five-day winning streak, and several major market benchmarks fell more than 1% on the day. Chinese trade numbers weren't as vigorous as many had hoped, and the corresponding impact on the...
THO: 75.21 (-1.56), CVGW: 65.58 (+0.07), OMER: 11.45 (-0.35)
Why Omeros Corporation Is Up Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 08, 11:43AM CST
IMAGE SOURCE: OMEROS CORPORATION. W hat: After reporting fourth-quarter financial results yesterday and indicating today that it's initiating a late-stage trial for a key drug in its pipeline, Omeros Corporation is skyrocketing 17.5%. So...
ALXN: 131.32 (-2.18), OMER: 11.45 (-0.35)
Omeros Corporation Initiates its Phase 3 Program for OMS721 in aHUS Following Meeting with FDA
BusinessWire - Tue Mar 08, 6:00AM CST
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that it has initiated its Phase 3 OMS721 program for the treatment of atypical hemolytic uremic syndrome (aHUS) after meeting with the U.S. Food and Drug Administration (FDA). OMS721 is Omeros' lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of thrombotic microangiopathies (TMAs), including aHUS. The FDA has awarded OMS721 both orphan drug designation for the treatment of TMAs and fast-track status for the treatment of aHUS.
OMER: 11.45 (-0.35)
Omeros Corporation Confirms OMS721 Phase 3 Development Plan with European Medicines Agency
PR Newswire - Thu Jul 28, 8:27AM CDT
Omeros Corporation (NASDAQ: OMER) today announced that it has received scientific advice from the European Medicines Agency (EMA) in connection with the company's OMS721 Phase 3 program for the treatment of atypical hemolytic uremic syndrome (aHUS). Based on this EMA advice, the company plans to run the same, single Phase 3 clinical program to support OMS721 marketing approval applications in both the U.S. and in the European Union for the treatment of aHUS. OMS721 is Omeros' lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of thrombotic microangiopathies (TMAs), including aHUS and hematopoietic stem cell transplant-related (HSCT) TMAs, and for the treatment of complement-related renal diseases. Omeros plans to commercialize OMS721 initially for administration as a subcutaneous injection.
OMER: 11.45 (-0.35)
Omeros to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
BusinessWire - Thu Jul 07, 6:00AM CDT
Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference in New York next week. The presentation is scheduled for Tuesday, July 12, 2016 at 10:45 a.m. EDT.
OMER: 11.45 (-0.35)
The Sub $1 Stock in the $800 Billion Cigarette Industry the Tobacco Giants Need to Stay Relevant
ACCESSWIRE - Mon May 23, 6:00AM CDT
WINDSOR, ON / ACCESSWIRE / May 23, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to bring to investors' attention how one little-known company, 22nd Century Group (NYSE MKT: XXII), has developed a revolutionary combustible cigarette that could give smokers exactly what they have been seeking, and drastically change the tobacco industry in the process. RAI: 49.84 (unch), PM: 99.89 (-0.26), BTI: 128.20 (+1.62), XXII: 0.91 (-0.01), MO: 67.57 (-0.08), ARDM: 4.78 (+0.11), OMER: 11.45 (-0.35)
Omeros Announces Debt Financing Transaction for $20 Million in Additional Funds
BusinessWire - Tue May 17, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) (the "Company"
today announced that it has entered into an amendment to its existing credit facility with Oxford Finance LLC ("Oxford" and East West Bank ("East West" to provide the Company with an additional $20 million in unrestricted cash by funding the remaining tranches of the facility. Omeros will issue warrants to the lenders, exercisable for seven years for up to 100,602 shares of the Company's common stock at an exercise price per share of $9.94, the closing price of the Company's stock on May 16, 2016. All loan payments will be interest-only until August 1, 2017. The final payment fee rate on the $20 million borrowed will increase from 5.25% to 6.25%, reflecting the accelerated draw-down of these additional funds. Omeros expects funding will occur on May 18, 2016. OMER: 11.45 (-0.35)
Omeros reports 1Q loss
Automated Insights - Tue May 10, 6:26AM CDT
SEATTLE (AP) _ Omeros Corporation (OMER) on Tuesday reported a loss of $20.5 million in its first quarter.
OMER: 11.45 (-0.35)
Omeros Corporation Reports First Quarter 2016 Financial Results
BusinessWire - Tue May 10, 6:20AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the first quarter of 2016, which include:
OMER: 11.45 (-0.35)
Omeros Corporation Announces Exclusive Middle East Distribution Agreement for OMIDRIA(R)
BusinessWire - Tue May 10, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced entry into an exclusive supply and distribution agreement for the sale of OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% in the Kingdom of Saudi Arabia, the United Arab Emirates and other countries in the Middle East with ITROM Trading Drug Store (ITROM). ITROM is Dubai-based and an internationally recognized pharmaceutical marketing and distribution company specializing in ophthalmology. Under the agreement, ITROM will be responsible for obtaining marketing authorizations for OMIDRIA within the licensed territory and for marketing, selling and distributing product supplied by Omeros. Existing ophthalmology medical sales representatives employed by ITROM are expected to be reinforced with additional medical sales representatives that will be dedicated to OMIDRIA.
OMER: 11.45 (-0.35)
Omeros Corporation to Announce First Quarter 2016 Financial Results on May 10, 2016
BusinessWire - Wed May 04, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its first quarter 2016 financial results for the period ended March 31, 2016, on Tuesday, May 10, 2016, before the market opens. Omeros management will host a conference call and webcast that day at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) to discuss the financial results.
OMER: 11.45 (-0.35)
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 4.23 (+0.04), CBMG: 14.72 (-0.10), OCAT: 8.47 (+0.01), ZBH: 129.94 (-1.12), PFE: 36.37 (-0.94), LLY: 82.90 (-0.28), GSK: 45.28 (+0.03), GLPG: 52.66 (-0.48), AXSM: 7.67 (-0.12), OMER: 11.45 (-0.35), CANF: 2.07 (-0.03), AST: 2.94 (unch), AKTX: 11.50 (unch)
Omeros Corporation Announces Independent Studies with OMIDRIA(R) to Be Presented at Upcoming Ophthalmology Congresses
BusinessWire - Tue Apr 26, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that new research related to the clinical utility of OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% and the importance of preempting intraoperative miosis and inflammation during cataract surgery will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting in Seattle, Washington, May 1 - 5, 2016, and the American Society of Cataract and Refractive Surgery (ASCRS) Congress in New Orleans, Louisiana, May 6 - 10, 2016. Presentations will address the beneficial effects demonstrated in case-controlled studies of OMIDRIA on complication rates, on use of pupil-expanding devices, on surgical times and on postoperative visual acuity.
OMER: 11.45 (-0.35)
Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases
BusinessWire - Wed Apr 20, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced initiation of patient dosing in its OMS721 Phase 2 program in corticosteroid-dependent renal diseases. The Phase 2 clinical trial of OMS721, the company's lead mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor being developed for complement-related diseases, is evaluating the effects of OMS721 on kidney function in patients with corticosteroid-dependent renal diseases. This new trial expands the company's MASP platform, which includes an OMS721 Phase 3 program in progress for the treatment of atypical hemolytic uremic syndrome (aHUS) as well as an ongoing Phase 2 program of OMS721 for the treatment of other thrombotic microangiopathies (TMAs).
OMER: 11.45 (-0.35)
Restless Legs Syndrome Pipeline Market 2016 Review Research
PR Newswire - Mon Apr 11, 7:30AM CDT
New market research titled "Restless Legs Syndrome - Pipeline Review, H1 2016" is a report that provides an overview of the Restless Legs Syndrome's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
OMER: 11.45 (-0.35)
Traumatic Brain Injury Pipeline Market 2016 Covering 37 Key Players
PR Newswire - Fri Apr 08, 5:00AM CDT
This 2016 report provides an overview of the Traumatic Brain Injury therapeutic pipeline and helps enhance decision making capabilities to create effective counter strategies & gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
LPTN: 1.95 (-0.02), OMER: 11.45 (-0.35), ATHX: 2.16 (-0.01), KPTI: 7.06 (-0.17), CUR: 0.22 (-0.01)
Omeros to Present at the 15th Annual Needham Healthcare Conference
BusinessWire - Thu Apr 07, 6:00AM CDT
Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 15th Annual Needham Healthcare Conference in New York next week. The presentation is scheduled for Wednesday, April 13, 2016, at 2:20 p.m. EDT.
OMER: 11.45 (-0.35)
Is This Upstart the Biggest Threat to Alexion Pharmaceuticals?
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 11, 8:02AM CST
Image source: Alexion Pharmaceuticals. Alexion Pharmaceuticals is a big player in the treatment of rare diseases, but its dominance in atypical hemolytic uremic syndrome (aHUS) could be in jeopardy if a soon-to-begin clinical trial at Omeros...
ALXN: 131.32 (-2.18), OMER: 11.45 (-0.35)
Atherosclerosis Pipeline: H2 2015 World Market Research Report
PR Newswire - Wed Mar 09, 6:30AM CST
Market research report titled "Atherosclerosis - Pipeline Review, H2 2015" provides an overview of the Atherosclerosis's therapeutic pipeline and enhances decision making capabilities to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
JNJ: 124.65 (-0.75), VCEL: 2.27 (+0.05), KNMD: (), OPK: 9.91 (-0.16), GILD: 80.19 (-0.27), MRK: 58.45 (-0.21), AZN: 33.86 (+0.02), OMER: 11.45 (-0.35)
Why Calavo Growers, Thor Industries, and Omeros Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Tue Mar 08, 6:45PM CST
Image: Calavo Growers. Tuesday ended the stock market's five-day winning streak, and several major market benchmarks fell more than 1% on the day. Chinese trade numbers weren't as vigorous as many had hoped, and the corresponding impact on the...
THO: 75.21 (-1.56), CVGW: 65.58 (+0.07), OMER: 11.45 (-0.35)
Why Omeros Corporation Is Up Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 08, 11:43AM CST
IMAGE SOURCE: OMEROS CORPORATION. W hat: After reporting fourth-quarter financial results yesterday and indicating today that it's initiating a late-stage trial for a key drug in its pipeline, Omeros Corporation is skyrocketing 17.5%. So...
ALXN: 131.32 (-2.18), OMER: 11.45 (-0.35)
Omeros Corporation Initiates its Phase 3 Program for OMS721 in aHUS Following Meeting with FDA
BusinessWire - Tue Mar 08, 6:00AM CST
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that it has initiated its Phase 3 OMS721 program for the treatment of atypical hemolytic uremic syndrome (aHUS) after meeting with the U.S. Food and Drug Administration (FDA). OMS721 is Omeros' lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of thrombotic microangiopathies (TMAs), including aHUS. The FDA has awarded OMS721 both orphan drug designation for the treatment of TMAs and fast-track status for the treatment of aHUS.
OMER: 11.45 (-0.35)
